SEC Form 424B3 filed by CM Life Sciences, Inc.

424B3 - Sema4 Holdings Corp. (0001818331) (Filer)

8-K - Sema4 Holdings Corp. (0001818331) (Filer)

S-8 - Sema4 Holdings Corp. (0001818331) (Filer)

Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, today announced the appointment of Andrew Kasarskis, PhD, to the newly established role of Chief Data Officer (CDO). Dr. Kasarskis brings more than 20 years of leadership and broad experience in industry and academia that includes a strong focus on digital analytics and genomics and internationally recognized research in the life sciences. At Sema4, he will be responsible for establishing additional structures and processes to further optimize the company's health intelligence platform and orchestrating data use and data science to support research, development, and innov

37% increase in fourth quarter test volumes (excluding COVID-19 tests) compared to the same period last year Record quarterly test volume of nearly 83,000 24% growth in fourth quarter revenue (excluding COVID-19 tests) compared to the same period last year Reiterating full year 2022 total revenue guidance of $215-225 million Sema4 to host conference call today at 4:30 p.m. ET STAMFORD, Conn., March 14, 2022 (GLOBE NEWSWIRE) -- Sema4 Holdings Corp. (NASDAQ:SMFR) ("Sema4"), an AI-driven genomic and clinical data intelligence platform company, today reported its financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on key strategic and ope

Sema4 Holdings Corp ("Sema4") to debut on Nasdaq as a publicly traded company dedicated to transforming healthcare by applying artificial intelligence and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human healthBusiness combination expected to result in ~$500 million in cash proceeds to Sema4 to accelerate organic and inorganic growthCombined company to trade on Nasdaq under ticker "SMFR" STAMFORD, Conn., July 22, 2021 (GLOBE NEWSWIRE) -- Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, today announced the completion of its business combination with CM Life

Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, today announced the appointment of renowned executive Jason Ryan to its Board of Directors. Mr. Ryan will begin serving on Sema4's Board of Directors upon his official appointment after Sema4 closes its previously announced business combination with CM Life Sciences (NASDAQ:CMLF), a special purpose acquisition company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210707005228/en/Jason Ryan (Photo: Business Wire) Mr. Ryan most recently served as Chief Operating and Financial Officer of Magenta Therapeutics (NA